Chiron / GlaxoSmithKline / Pfizer Inc. / Merck / Genentech Inc. / Protein-Based Pharmaceuticals / Baxter Healthcare Corp. / Biogen Inc. / Wyeth / Immunex Inc. / Merck & Co. Inc. / Immunex Corporation / Johnson & Johnson / Amgen Inc. / Aventis / The Genetics Institute Inc. / Lilly / Biogen Idec / Genzyme Corp. / Idec Pharmaceuticals / National Institutes / Serono Inc. / Dole / See Amgen Inc. / See Wyeth Labs. / Centocor Inc. / Scios Inc. / /
RECOMBINANT UNIVERSITY / Columbia University / Stable Integration / University Transformed / Statutory Bar / /
IndustryTerm
recombinant protein pharmaceuticals / machinery / desired proteinaceous product / pharmaceutical agents / proteinaceous product / secretive biotechnology / biotechnology research / innumerable practical applications / pharmaceuticals / biological tool / biotechnology ni dustry / recombinant protein product / manufacturing / transformation technology / chemicals / chemical synthesis / selective media / pharmaceutical / protein purification technology / ground-breaking technology / biotechnology revolution / scientific protocol / /
MedicalCondition
Pseudomonas / strain / /
Organization
Columbia University / Supreme Court / DNA / Genetics Institute / Columbia Univ. / National Institute of Health / Harvard / Congress / federal government / office of Tech / Univ . of Cal. / /
Person
Ric / Tom Abate / Stanley N. Cohen / Angel Pellicer / Elizabeth H. Szybalska / Sue Columbia / Axel Lab / Paul Berg / BRUCE ALBERTS ET AL / Ken Howard / Herbert W. Boyer / Diane M. Robins / Golden Goose / Axel Patent / Jane Larson / Rachel M. Mitton-Fry / Gary Walsh / John L. Gueriguian / Herbert Pardes / Ted Agres / Grant Numbers / Richard Axel / /
Harvard Journal of Law & Technology Volume 17, Number 2 Spring 2004 RECENT D EVELOPMENTS Axel Patent Litigation, e.g., Genentech, Inc. v. Tr. of Columbia Univ., N.D. Cal. 2003, No. 3:03-cv-01603..........................